樂觀
$14.03
情境價格
$11.250
-0.187 (-1.66%)收盤時
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
While Brainsway Ltd shows promising growth potential with a current price of $11.25 and a forward P/E ratio of 17.92, the RSI of 32.42 indicates it is currently oversold. The recent FDA approval for their Deep TMS technology and a strategic investment of $3 million in Radial Health are positive catalysts. However, the stock has seen a 15.48% decline over the past 20 days, suggesting caution. Given these factors, it may be wise to hold rather than buy at this moment.
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

BrainsWay Partners with IPMG to Enhance Mental Health Treatments

BrainsWay Expands Medical Policy Coverage for SWIFT TMS Protocol

BrainsWay Announces Pilot Study Results on Depression Treatment

BrainsWay Publishes New Data on Depression Treatment

BrainsWay Reports 35% Revenue Growth in Q2 2026
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).
While Brainsway Ltd shows promising growth potential with a current price of $11.25 and a forward P/E ratio of 17.92, the RSI of 32.42 indicates it is currently oversold. The recent FDA approval for their Deep TMS technology and a strategic investment of $3 million in Radial Health are positive catalysts. However, the stock has seen a 15.48% decline over the past 20 days, suggesting caution. Given these factors, it may be wise to hold rather than buy at this moment.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。